The GI Pathway and Chronic Disease
A host of modern chronic diseases, such as obesity, NAFLD/NASH, IBD, and diabetes, originate in the GI pathway.
Weight Management and Chronic Disease
Half of all Americans report a desire to lose weight, but most attempts to maintain a healthy weight end in failure, and obesity rates continue to rise, increasing the burden on the health system.
Obesity is a medical disease that increases the risk for over 30 health conditions.
Current approaches to treat obesity, including surgery and prescription medications, are recommended to only a small percentage of individuals with obesity. These treatment options also have significant unwanted adverse events and/or limited efficacy.Learn how Gelesis is different
Type 2 Diabetes: A growing epidemic
Obesity is a major risk factor for developing prediabetes and diabetes. Approzimately 85% of patients with type 2 diabetes are overweight or have obesity. In the United States, around 26 million adults have type 2 diabetes and an estimated 86 million have prediabetes. Approximately 312 million people have type 2 diabetes worldwide. A modest 5-7% weight loss has been shown to prevent conversion from prediabetes to diabetes in over 50% of patients.
A safe, effective treatment that could induce weight loss in people with prediabetes could potentially have a major impact on human health and may also result in tremendous savings for the healthcare system.
Inflammatory GI Disease
Within the GI pathway, the health of the epithelial barrier and mucus layer may play an important role in the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as diseases involving inflammation of the intestines, such as IBD, Celiac Disease, and Crohn's Disease.
NAFLD/NASH is considered the most common liver disease in developed nations. NAFLD is defined as the accumulation of excessive fat in the liver in the absence of excessive drinking of alcohol and any secondary cause.
An estimated 70-80% of people with obesity have NAFLD.
For more information, please visit: